Skip to content

A Clinical Study Program about Treatment of Migraine - Depression Syndrome by Jieyu Decoction

A Clinical Study Program about Treatment of Migraine - Depression Syndrome by Jieyu Decoction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012419
Enrollment
Unknown
Registered
2017-08-19
Start date
2017-08-03
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine - Depression Syndrome

Interventions

treatment group:Oral Jieyu therapy
??? ??? control group:Venlafaxine capsules

Sponsors

Shanghai TCM-integrated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 85 Years

Inclusion criteria

Inclusion criteria: According to the "International Classification of Headache Disorders" version 2 (CHD-II) [5] diagnostic criteria diagnosed as migraine, and Hamilton Depression Scale (HAMD) (17) score greater than 7 points less than 35 points belong to light Depression in patients with depression

Exclusion criteria

Exclusion criteria: 1. age under the age of 18 or 65 years, pregnancy and breastfeeding; 2. hypertensive patients, venlafaxine hydrochloride allergies or allergies; 3. this migraine has been taken alcohol abusers or the use of analgesic, sedative hypnotics; 4. combined with heart, lung, liver, kidney and other vital organs of organic disease patients; 5. other mental illness other than depression; 6. other organic diseases caused by headaches or other symptoms associated with the onset of headaches.

Design outcomes

Primary

MeasureTime frame
Integrative scores of headache;the Migraine-Specific Quality of Life Questionnaire Version 2.1, MSQ2.1;Hamilton Depression Scale, HAMD;

Countries

China

Contacts

Public ContactChangde Wang

Shanghai TCM-integrated Hospital

liuxiaoying2005@126.com+86 15921776521

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026